MedTrace Logo

Application of ihMT MRI in Multiple Sclerosis

NCT03600779 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-08-06

No results posted yet for this study

Summary

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Conditions

  • Sclerosis, Multiple

Interventions

DEVICE

inhomogeneous Magnetisation Transfer (ihMT) sequence

robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T

DEVICE

inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T

robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • EMILIE GARRIDO PRADALIE · APHM

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-14
Primary Completion
2026-02-13
Completion
2027-02-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600779 on ClinicalTrials.gov